🚀 VC round data is live in beta, check it out!
PTC Therapeutics Valuation Multiples
Discover revenue and EBITDA valuation multiples for PTC Therapeutics and similar public comparables like Yuhan, Bachem, Mirum Pharmaceuticals, Gan and Lee and more.
PTC Therapeutics Overview
About PTC Therapeutics
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Founded
1998
HQ
Employees
1.0K
Website
Sectors
Financials (LTM)
EV
$6B
PTC Therapeutics Financials
PTC Therapeutics reported last 12-month revenue of $2B and EBITDA of $716M.
In the same LTM period, PTC Therapeutics generated $1B in gross profit, $716M in EBITDA, and $493M in net income.
Revenue (LTM)
PTC Therapeutics P&L
In the most recent fiscal year, PTC Therapeutics reported revenue of $2B and EBITDA of $905M.
PTC Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 97% | XXX | 97% | XXX | XXX | XXX |
| EBITDA | $716M | XXX | $905M | XXX | XXX | XXX |
| EBITDA Margin | 47% | XXX | 52% | XXX | XXX | XXX |
| EBIT Margin | 43% | XXX | 50% | XXX | XXX | XXX |
| Net Profit | $493M | XXX | $683M | XXX | XXX | XXX |
| Net Margin | 32% | XXX | 39% | XXX | XXX | XXX |
| Net Debt | — | — | $2B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
PTC Therapeutics Stock Performance
PTC Therapeutics has current market cap of $5B, and enterprise value of $6B.
Market Cap Evolution
PTC Therapeutics' stock price is $66.34.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $5B | 0.0% | XXX | XXX | XXX | $8.25 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPTC Therapeutics Valuation Multiples
PTC Therapeutics trades at 4.1x EV/Revenue multiple, and 8.7x EV/EBITDA.
EV / Revenue (LTM)
PTC Therapeutics Financial Valuation Multiples
As of April 1, 2026, PTC Therapeutics has market cap of $5B and EV of $6B.
Equity research analysts estimate PTC Therapeutics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PTC Therapeutics has a P/E ratio of 11.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $5B | XXX | $5B | XXX | XXX | XXX |
| EV (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | 3.6x | XXX | XXX | XXX |
| EV/EBITDA | 8.7x | XXX | 6.9x | XXX | XXX | XXX |
| EV/EBIT | 9.4x | XXX | 7.2x | XXX | XXX | XXX |
| EV/Gross Profit | 4.2x | XXX | 3.7x | XXX | XXX | XXX |
| P/E | 11.1x | XXX | 8.0x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 15.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PTC Therapeutics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
PTC Therapeutics Margins & Growth Rates
PTC Therapeutics' revenue in the last 12 month declined by (37%).
PTC Therapeutics' revenue per employee in the last FY averaged $1.7M, while opex per employee averaged $0.8M for the same period.
PTC Therapeutics' rule of 40 is (31%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PTC Therapeutics' rule of X is (101%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
PTC Therapeutics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | (37%) | XXX | (46%) | XXX | XXX | XXX |
| EBITDA Margin | 47% | XXX | 52% | XXX | XXX | XXX |
| EBITDA Growth | (76%) | XXX | (85%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (31%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (101%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $1.7M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.8M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 29% | XXX | 26% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 48% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
PTC Therapeutics Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Yuhan | XXX | XXX | XXX | XXX | XXX | XXX |
| Bachem | XXX | XXX | XXX | XXX | XXX | XXX |
| Mirum Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Gan and Lee | XXX | XXX | XXX | XXX | XXX | XXX |
| Immunovant | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PTC Therapeutics M&A Activity
PTC Therapeutics acquired XXX companies to date.
Last acquisition by PTC Therapeutics was on XXXXXXXX, XXXXX. PTC Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by PTC Therapeutics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPTC Therapeutics Investment Activity
PTC Therapeutics invested in XXX companies to date.
PTC Therapeutics made its latest investment on XXXXXXXX, XXXXX. PTC Therapeutics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by PTC Therapeutics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PTC Therapeutics
| When was PTC Therapeutics founded? | PTC Therapeutics was founded in 1998. |
| Where is PTC Therapeutics headquartered? | PTC Therapeutics is headquartered in United States. |
| How many employees does PTC Therapeutics have? | As of today, PTC Therapeutics has over 1K employees. |
| Who is the CEO of PTC Therapeutics? | PTC Therapeutics' CEO is Matthew B. Klein. |
| Is PTC Therapeutics publicly listed? | Yes, PTC Therapeutics is a public company listed on Nasdaq. |
| What is the stock symbol of PTC Therapeutics? | PTC Therapeutics trades under PTCT ticker. |
| When did PTC Therapeutics go public? | PTC Therapeutics went public in 2013. |
| Who are competitors of PTC Therapeutics? | PTC Therapeutics main competitors are Yuhan, Bachem, Mirum Pharmaceuticals, Gan and Lee. |
| What is the current market cap of PTC Therapeutics? | PTC Therapeutics' current market cap is $5B. |
| What is the current revenue of PTC Therapeutics? | PTC Therapeutics' last 12 months revenue is $2B. |
| What is the current revenue growth of PTC Therapeutics? | PTC Therapeutics revenue growth (NTM/LTM) is (37%). |
| What is the current EV/Revenue multiple of PTC Therapeutics? | Current revenue multiple of PTC Therapeutics is 4.1x. |
| Is PTC Therapeutics profitable? | Yes, PTC Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of PTC Therapeutics? | PTC Therapeutics' last 12 months EBITDA is $716M. |
| What is PTC Therapeutics' EBITDA margin? | PTC Therapeutics' last 12 months EBITDA margin is 47%. |
| What is the current EV/EBITDA multiple of PTC Therapeutics? | Current EBITDA multiple of PTC Therapeutics is 8.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.